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Irreversible electroporation of the 
liver: is there a safe limit to the 
ablation volume?
P. Sánchez-Velázquez1, Q. Castellví2, A. Villanueva3, R. Quesada1, C. Pañella1, M. Cáceres1, 
D. Dorcaratto1, A. Andaluz4, X. Moll4, M. Trujillo5, J. M. Burdío6, E. Berjano5, L. Grande1, 
A. Ivorra2 & F. Burdío1
Irreversible electroporation is a fast-growing liver ablation technique. Although safety has been well 
documented in small ablations, our aim is to assess its safety and feasibility when a large portion of 
liver is ablated. Eighty-seven mice were subjected to high voltage pulses directly delivered across 
parallel plate electrodes comprising around 40% of mouse liver. One group consisted in 55 athymic-
nude, in which a tumor from the KM12C cell line was grown and the other thirty-two C57-Bl6 non-
tumoral mice. Both groups were subsequently divided into subsets according to the delivered field 
strength (1000 V/cm, 2000 V/cm) and whether or not they received anti-hyperkalemia therapy. Early 
mortality (less than 24 hours post-IRE) in the 2000 V/cm group was observed and revealed considerably 
higher mean potassium levels. In contrast, the animals subjected to a 2000 V/cm field treated with the 
anti-hyperkalemia therapy had higher survival rates (OR = 0.1, 95%CI = 0.02–0.32, p < 0.001). Early 
mortality also depended on the electric field magnitude of the IRE protocol, as mice given 1000 V/cm  
survived longer than those given 2000 V/cm (OR = 4.7, 95%CI = 1.8–11.8, p = 0.001). Our findings 
suggest that ionic disturbances, mainly due to potassium alterations, should be warned and envisioned 
when large volume ablations are performed by IRE.
Electroporation (EP) is a biophysical phenomenon becoming increasingly used as an ablation technique. Although 
the mechanism of EP is not yet fully understood, it is widely accepted that high electric field pulses delivered 
across tissues cause pores in the cell bilayer membrane thereby increasing its permeability. When these pulses are 
delivered with sufficient magnitude and duration, cell death is achieved and the process is defined as irreversible 
electroporation (IRE)1–4. IRE has shown complete responses and reduced tumor size after treatment of several 
solid tumors5–10.
As only 10–20% candidates for liver surgery are potentially resectable11, ablative techniques are perceived as 
promising alternatives and assessed in terms of their capability to ablate large volumes12. Until now, clinical IRE 
is typically performed in small tumors (diameter < 3 cm). However, there are some pioneering studies indicating 
a growing interest in treating larger volumes. For instance, use of IRE in large tumor models was evaluated by Lee 
et al. who achieved a maximum ablated volume of 22.1 cm3 in a liver rabbit model (between 25–32% of total vol-
ume)13 with favourable outcomes14. Appelbaum et al. demonstrated that IRE application was clinically acceptable 
addressed to tumors > 6 cm15.
Our group has been working on a novel IRE approach carried out in an immunosuppressed murine model of 
liver metastases in which the IRE ablation volume was unusually large16: we delivered pulses across two parallel 
plates that comprise two segments of the left liver which corresponds to nearly 40% of its volume17,18. Unlike 
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thermal ablation techniques, IRE preserves the extracellular matrix and this may allow novel treatment para-
digms. Our aim was to assess whether a large ablation could achieve the antitumor effect while preserving suffi-
cient the liver parenchyma and function, in order to concomitantly ablate several nodules with a single applicator.
Safety of IRE has been extensively reported when moderate volumes are ablated19–22. However, our prelimi-
nary results showed high post-treatment mortality when larger volumes were treated.
We hypothesized that ablating such volume might had caused a massive release of intracellular contents into 
the bloodstream. We deemed that release of potassium was probably a major mortality cause as most deaths 
occurred a few minutes after delivery of the pulses. In the present study, to test this hypothesis, a subset of the 
animals was treated with intensive anti-hyperkalemia therapy. In addition, since we were concerned that immu-
nosuppressed mice may be especially susceptible to IRE23, we conducted the same treatment in a subset of immu-
nocompetent animals.
Thus, the aim of this study was to assess the safety and feasibility of IRE when large volume of liver is subjected 
to ablation.
Materials and Methods
All aspects of this study were performed as part of an animal research protocol, in accordance with the guidelines 
approved by the Government of Catalonia’s Animal Care Committee (procedure FBP-13-1474, DAAM: 7016). 
These guidelines follow the Directive 2010/63/EU of the European Parliament and of the Council of 22 September 
2010 on the protection of animals used for scientific purposes. All authors had control of the data and the infor-
mation submitted for publication.
Animal model. Two strains of six-week-old male mice (n: 87), immunodeficient athymic-nude (Harlan lab-
oratories, Indianapolis, IN, USA) and immunocompetent C57-Bl6 (Charles River Laboratories, New York, NY, 
USA) were acquired and maintained under standard conditions with a laboratory diet and water ad libitum.
The groups were differentiated according to the IRE protocol applied, the mouse strain, and whether or not 
they received specific anti-hyperkalemia therapy (detailed in Table 1).
Tumor implantation. The KM12C human colon cancer cell line was implanted in immunodeficent mice 
(n: 55). Tumors subcutaneously implanted and passaged in nude mice were extracted to prepare tumor frag-
ments of 2 × 2 × 2 mm3 and then implanted. Animals were anesthetized with a mixture of isofluorane and inhaled 
oxygen and analgesia was provided with buprenorphine (0.05–0.1 mg/kg SC) and meloxicam (1–3 mg/kg SC). 
After anaesthesia, a subxiphoid laparotomy was performed and the left lobe of the liver exposed. The tumor was 
stitched to the hepatic capsule using a monofilament suture of 6/0 prolene. The abdominal muscle layer was 
closed with a running suture of vicryl 5/0, and the skin with a single silk suture.
Following initial implantation, 15 days were allowed for tumor growth. All the animals from the initial 55 
implanted animals developed a tumor suitable for an IRE procedure and the treatment was applied after the 
growth period.
Irreversible electroporation treatment. After exposing the liver, plate electrodes were placed accord-
ing to Fig. 1A,C. Not only the whole tumor was placed between the two parallel plate electrodes, but also both 
two segments of the left mouse liver, which represents around 40% of total size24. In contrast to needle elec-
trodes, this approach ensures a quite uniform electric field across the treated volume thereby facilitating analysis. 
Furthermore, for further improving electric field uniformity a partially conductive gel (Aquasonic 100 Sterile, 
Parker Laboratories, Fairfield, NJ, USA) was applied between the two parallel plate electrodes25.
As a wide range of field magnitudes has been reported for complete ablation by IRE26,27, we evaluated two 
different magnitudes: 1000 V/cm and 2000 V/cm and a subset of animals were sham operated. The custom made 
generator was programmed to deliver ten sequences of ten pulses with a pulse duration of 100 μs and a repetition 
frequency of 1 Hz with a 10 s pause in between the ten pulses sequences.
During the first 72 h after surgery all the animals were given two additional doses of buprenorphine 
(0.05–1 mg/kg SC) and meloxicam (1–3 mg/kg SC), spaced out over 12 h increments.
Pharmacological therapy against hyperkalemia. Prior to surgery, the set of animals corresponding 
to this treatment group (n: 42) were pre-hydrated with 200 μL of 0.9% NaCl (i.p.) solution every 24 h for two 
Mice strain
IRE 
Protocol 
(V/cm)
Anti-
hyperkalemia 
therapy N = 87
Survivors at 24 h
Amount
Survival days 
mean (range)
Tumoral athymic-Nude (ID)
SHAM No 15 15 (100%) 74.5 (49–122)
1000 V/cm No 11 8 (72.7%) 63.1 (2–121)
2000 V/cm
No 9 0 (0%) —
Yes 20 16 (80%) 112.6 (28–176)
C57-Bl6 (IC)
1000 V/cm No 2 2 (100%) *
2000 V/cm
No 8 2 (25%) *
Yes 22 10 (45.5%) *
Table 1.  Classification of the different groups of animals. *Animals of the non-tumoral group were 
euthanized after 7 days.
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consecutive days. Calcium gluconate (GC) was injected in the preoperative care in two boluses, both intrave-
nously (i.v.) and intraperitoneally (i.p.) at a dose of 100 mg/kg28. To prevent hyperkalemia, a furosemide i.v. 
bolus (4 mg/kg) was administered and during anaesthesia induction oxygen was mixed with inhaled salbutamol 
(100mcg). After the procedure, sodium bicarbonate (NaHCO3) i.p. was administered before the closure of the 
abdominal wall at a dose of 1 mEq/kg28.
Analytical tests at 10 min post-IRE were performed to quantify blood electrolytes in all the animals with an 
i-STAT® device (Abbott Point of Care Inc, Princeton, NJ, USA). Blood samples obtained by a single puncture in 
the saphena vein. Serum levels of sodium (Na+), potassium (K+), and HCO3− were measured immediately after 
the extraction using the i-STAT® .
Estimation of electroporated volume. The following parameters were evaluated in the liver samples 
harvested during the in vivo experiments: total liver weight, electroporated liver weight, total liver volume and 
electroporated liver volume. A precision scale was used to determine the weight. Volume was measured by plac-
ing the tissue samples in a laboratory graduated cylinder filled with water and quantifying the volume displaced.
Statistical Analysis. All the statistics were processed by the SPSS statistical software package (SPSS, version 
20, IBM, Armonk, NY, USA) and expressed as mean ± standard deviation.
The Kolmogorov–Smirnov test was used to determine the distribution of the variables. The Student’s t-test 
was used to make pairwise comparisons of normally distributed parameters and the Mann-Whitney U test was 
used for non-parametric data. The influence of hyperkalemia and IRE protocol on mortality was determined by 
univariable and multivariable logistic regression analyses. Results were expressed as Odds Ratio (OR) with 95% 
Confidence Interval (CI). Tests were considered statistically significant with a p-value of < 0.05.
Results
Irreversible electroporation of a large hepatic volume produces severe hyperkalemia. Thirty-
four from the total of electroporated animals (47.2%) died in the first 24 hours. Specifically, this early mortality 
occurred in 88% of the animals subjected to a 2000 V/cm field with no anti-hyperkalemia therapy (Table 1). 
There were no deaths during the application of the pulses, after which the animals were lethargic and tachypneic, 
presumably to compensate metabolic acidosis (Kussmaul breathing). Individuals showed lack of grooming and 
locomotion and eventually died (death times ranged from 5 minutes to 24 hours). At necropsy, hyperemia and 
vascular congestion were observed in the section of the liver that had received the pulses. However, no structural 
damage or intra-abdominal haemorrhages were noticed that could explain the early death of these animals. No 
other findings were encountered at the necropsies.
The serum potassium levels of all the animals were separately analyzed, considering 24-hour survival as a 
cut off value. Mean potassium levels were remarkably lower in the up to 24 h survival group (7.74 ± 1.7 mmol/L) 
than in the other group (9.49 ± 4.1 mmol/L), reaching statistical significance (p = 0.001). Logistic regression was 
applied to estimate the effect of hyperkalemia on survival. The crude odds ratio (OR) was 1.37 (95%CI = 1.07–1.73, 
p = 0.01), which indicated a significantly higher value of potassium in the animals that did not survive up to 24 h 
(Table 2). However, the group differences in sodium or HCO3 levels did not reach statistical significance.
Figure 1. (A,C) Anterior and lateral view showing the plate electrodes placement on the targeted hepatic lobe 
in both strains of mice. (B) Photograph reveals the appearance of the electroporated left liver with the tumor in 
ID mice. (D) Hyperemic appearance of the left liver after the IRE in IC mice (without tumor).
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The mean electroporated volume was 548.7 μL, which represented 37.9% of the mean liver volume (1448 μL). 
In terms of weight, the mean electroporated mass was 561.8 mg, or 38.6% of the mean liver mass (1456 mg).
Early mortality depends on the electric field magnitude of the IRE protocol. As mentioned above, 
we observed that 88% of the animals that had not received anti-hyperkalemia treatment and given the highest 
intensity (2000 V/cm) died between 15 minutes to 24 hours after application. On the other hand, only 23.1% of 
those treated with 1000 V/cm protocol died in the first 24 h after the IRE-procedure and showed a similar symp-
tomatology to those belonging to the groups treated at 2000 V/cm. The remaining mice of the 1000V/cm group 
(77.9%) achieved a longer overall median survival. The subset of sham-operated animals presented an uneventful 
postoperative course in the first 24 h, remaining active with normal food intake and no hunched posture. No 
further alterations were noticed.
Logistic regression was applied to estimate the effect of the different IRE magnitudes on early survival. The 
protocols were categorized considering two groups; those that had received the maximum intensity (2000 V/cm) 
and those that had not, again using the 24-hour cut-off value. The odds ratio (OR) of animals receiving 2000 V/cm 
protocol compared to the rest was 4.7 (95%CI = 1.8–11.8, p = 0.001), which indicates that receiving an IRE pro-
tocol of 2000 V/cm increased the risk of death by four times in the first 24 h post-IRE (Table 2).
Management of electrolyte imbalances increases early survival after Irreversible 
Electroporation of a large volume of tissue. As shown in the previous section, the animals that 
received an IRE-protocol of 2000 V/cm had a poorer survival rate than the others. To ascertain the efficacy of the 
anti-hyperkalemia therapy, we analyzed separately the survival rate of the animals that received maximum voltage 
(2000 V/cm) plus anti-hyperkalemia therapy and those who did not receive the therapy.
Univariable logistic regression analyses revealed that the protocol 2000 V/cm animals that received the 
anti-hyperkalemia therapy had dramatically lower death rates in the first 24 h post-IRE than the other group 
(Table 2). (OR = 0.1; 95%CI = 0.02–0.32, p < 0.001).
Multivariable model ROC curve. To further assess the contribution of hyperkalemia, the IRE protocol and 
anti-hyperkalemia therapy to the survival rate and to avoid potential confounders, all the significant variables 
from the univariable analyses were included in a multivariable model (Table 2). Three variables were statistically 
significant: (i) IRE protocol 2000 V/cm (OR = 17.8; 95%CI = 2.5–125.6, p < 0.004), (ii) postoperative hyper-
kalemia (OR = 1.4, 95%CI = 1.0–1.9, p < 0.028) and (iii) medical treatment against hyperkalemia (OR = 0.3, 
95%CI = 0.1–0.8, p < 0.023). The area under the ROC curve was 0.9 (95%CI = 0.84–0.99, p < 0.001) for the logis-
tic regression model, which reveals very good goodness-of-fit.
Histopathological evaluation. The electroporated area of the liver showed infiltration of histocytes and 
lymphocytes, extensive areas of vascular congestion and interstitial oedema around hepatocytes, but no evidence 
of damage in the architecture of the hepatic sinusoids. Hepatic cells were surrounded by an eosinophil inflamma-
tory infiltrate. The presence of fibrin deposits between the vascular layers and the observation of loose perivas-
cular oedema on vessels confirmed that there was enhanced vascular permeability. Post-IRE tissue histological 
examination treatment of tumoral mice revealed extensive tumor necrosis (Fig. 2). In some of the tumors there 
were no signs of remnant tumoral cells while in other cases residual viable tumoral cells were still observed.
Discussion
Our results revealed early mortality (< 24 hours) in 47.2% of the total animals when any IRE protocol was applied 
involving a large liver volume and strong correlation between the electric field strength and this early mortality. 
However we were able to treat the diselectrolytemia and reduce the early mortality that occurred in 88% of the 
animals subjected to a 2000 V/cm field when no anti-hyperkalemia therapy was applied. This phenomenon has 
been observed in two completely different strains of mice with and without tumors.
Our hypothesis is that because of the increase in cell membrane permeability caused by electroporation cer-
tain potentially dangerous intracellular species freely diffuse from the intracellular medium to the extracellular 
medium. This phenomenon would be comparable to that of tumor lysis syndrome that occurs at the beginning 
of treatment with chemotherapeutics, in which tumor cells release intracellular products to bloodstream that 
overwhelm the excretory system29,30. In particular, we hypothesize that, in our study, released potassium ions 
were the major mortality cause as most deaths occurred within a few minutes after delivery of the pulsed electric 
fields. Potassium is one of the ions found in greater intracellular concentration31 (98% of the body’s potassium 
is in the intracellular fluid in a concentration of about 140 mmol/L). Cellular potassium levels are regulated by 
Na-K-ATPase and a passive leak mechanism driven by the electrochemical gradient favours potassium leaving 
the cell32.
Univariate Multivariate
OR 95% CI P OR 95% CI P
Postoperative hyperkalemia 1.4 1.1–1.7 0.01 1.4 1.0–1.9 0.028
IRE protocol 2000V/cm 4.7 1.8–11.8 0.001 17.8 2.5–125.6 < 0.004
Medical treatment against 
hyperkalemia 0.1 0.02–0.32 < 0.001 0.3 0.1–0.8 < 0.023
Table 2.  Univariable and Multivariable analyses in mice of the group of 24 h-survival.
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It has been reported that potassium values over 6.5 mmol/L can cause abnormalities in the electrocardiogram 
(ECG) and lead to potentially fatal ventricular arrhythmias. As is evident in the results mean potassium levels in 
the lower survival group was 9.49 ± 4.11 mmol/L, which exceeds the upper limit of normality (serum potassium 
values in mice: 5.1–10.4 mmol/L)28.
We presume that the larger the ablation target volume, the greater the disturbances expected in the homeosta-
sis, and hence the higher the risk of early mortality. Ball et al. demonstrated slight metabolic acidosis and hyper-
kalemia in 4 subjects from a group of 28 patients (14.3%) in which IRE was applied for ablation19. It was suggested 
that diselectrolitemia occurred in individuals who underwent ablation of very large tumors. However, this seems 
to be the only human study in which these alterations have been reported.
In a recent prospective multicenter study on 150 patients undergoing IRE − to our knowledge the largest human 
series published − high morbidity was found but no acid-base balance disorders were described33. In that study 
bipolar or monopolar probes were used to apply pulses, achieving a maximum ablation volume of 3.8 cm in diam-
eter, which is probably not enough to produce the expected effects. Other studies in which IRE was used for hepa-
tocellular carcinoma (CHC) ablation reported a maximum ablation diameter of 3.5 cm34. It has been described that 
the success rate of IRE rapidly decreases with the tumor size 12. In a recent systematic review, Scheffer et al. showed 
that, while from 67 to 100% primary efficacy was obtained in small lesions, efficacy dropped dramatically to 45% in 
large tumors35. It has been suggested that the cause is incomplete ablation of large tumors because of limited cover-
age by existing electrodes and generators33. Therefore, technological advances in ablating larger volumes with larger 
fields can be anticipated and dangerous metabolic acidosis and hyperkalemia could be manifested in the future.
Additional studies are required to consider this IRE approach. With improved surgical techniques and chemo-
therapy, surgically unresectable tumors are limited to large, multifocal tumors or to those located in difficult situa-
tions. Although IRE has been shown to avoid injury to the bile ducts and vessels27, little is known about its results 
when applied to large areas. In this context irreversible electroporation becomes both promising and a challenge.
To our knowledge this is the first study in which it is revealed that life threatening electrolytic disturbances occur 
after IRE ablation of a large portion (40%) of the liver. Although in current clinical practice such ablation volume is 
improbable, our results should serve as a warning to clinicians performing multiple or large ablations. Large liver 
ablations by IRE are being assayed in animal models and, presumably, will be tried in humans once the generators are 
able to apply the required electric fields and currents. It must be noted that the safety threshold remains unknown.
In conclusion, we consider that ionic imbalances produced by IRE are not an absolute contraindication for its 
use. Not certainly now, because the ablated volumes are too small, but also not in the future because, as our study 
shows, it will be possible to manage those imbalances. However, intensive patient monitoring, and in particular of 
his or her ionogram, will of course be necessary to treat possible imbalances caused by IRE, for which therapeutic 
approaches can be envisioned.
Figure 2. (A) Representative liver showing the macroscopic effect of electroporation in the treated left liver.  
(B) Extensive tumor necrosis after IRE is shown in microscope detail. Histological analysis of both liver lobes by 
HE histological staining revealed differences between the electroporated liver (D) and control (C).
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